Drug Channels
517 FOLLOWERS
Expert insights by Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system .
Drug Channels
1d ago
Adam J. Fein, Ph.D., president of Drug Channels Institute (DCI) and the author of Drug Channels, invites you to join him for DCI’s new live video webinar:
Drug Channels Outlook 2025
This event will be broadcast live on
Friday, December 13, 2024,
from 12:00 p.m. to 1:30 p.m. ET
This post describes the event and explains how to purchase a registration. (Or, just click here to order.) The webinar will be broadcast from the Drug Channels studio in beautiful downtown Philadelphia.
This event is part of The Drug Channels 2024 Video Webinar Series. (Please note that our December 2024 webinar is ..read more
Drug Channels
6d ago
Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx.
Chris examines three key trends that will affect patient support programs: the Inflation Reduction Act (IRA), legal/regulatory battles over copay adjustment programs, and uncertainties following a national election. He then outlines three actions that should guide manufacturers' preparation.
To learn more, register for ConnectiveRx’s free webinar on December 11: The Perfect Storm? Patient Support Programming in 2025 and Beyond.
Read on for Chris’s insights.
Read more »
© 2006-2024 HMP Omnimedi ..read more
Drug Channels
1w ago
Here on Drug Channels, we have long highlighted the boom in provider-administered biosimilars. In contrast to the pharmacy market, adoption of these biosimilars is growing, prices are dropping, and formulary barriers continue to fall.
Novel transparency information reveals that this good news doesn’t always translate into savings. Below, we rely on a unique data set from Turquoise Health to examine how much four national commercial health plans—Aetna, Anthem, Cigna, and UnitedHealthcare—paid hospitals for Avastin and its two most significant biosimilar competitors.
As we demonstrate, healt ..read more
Drug Channels
1w ago
Today’s guest post comes from Kimberley Chiang, Vice President of Biopharma Commercial Solutions at CoverMyMeds
Kimberley highlghts the crucial roles of field reimbursement managers in removing access and reimbursement barriers. She then identifies the keys to successful implementation of field reimbursement services.
To learn more, register for CoverMyMeds' November 13, 2024, webinar: Specialty Therapies & Field Reimbursement Services: Driving Better Outcomes for Brands and Patients.
Read on for Kimberley’s insights.
Read more »
© 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Ins ..read more
Drug Channels
2w ago
Eeek! It's time for Drug Channels’ Halloween roundup of terrifying tales to share with your ghoulish fiends. This month’s tricks and treats:
Spooky! Blue Shield of California frightens away the gross-to-net bubble with its Humira biosimilar strategy
Vampiric! Prior authorization sinks its fangs into providers’ time
Wicked! How the IRA will put a stake through specialty physician practices
Eerie! Google’s monstrous AI podcasts leave me petrified
Zoinks! Join the vampire hunters at Drug Channels Institute
Plus, Dr. Glaucomflecken tells us a frightening tale of copayments.
P.S. Stretc ..read more
Drug Channels
2w ago
Today’s guest post comes from Shabbir Ahmed, Chief Commercial Officer at CareMetx.
Shabbir explains the barriers that providers face when dealing with branded portals for multiple products. He then maintains that patients can access new therapies more quickly when the manufacturer relies on a brand-agnostic hub connected to a large network of providers and integrated with the systems those providers use daily.
To learn more, download CareMetx’s new 2024 Patient Services Report: Revealing Manufacturer Priorities: Patients Naturally Take Center Stage.
Read on for Shabbir’s insights.
Re ..read more
Drug Channels
3w ago
Reality has again failed to support the spin surrounding the 340B Drug Pricing Program.
For 2023, discounted purchases under the 340B program reached a record $66.3 billion—an astounding $12.6 billion (+23.4%) higher than its 2022 counterpart. The gross-to-net difference between list prices and discounted 340B purchases also grew, to $57.8 billion (+$5.5 billion). 340B purchases are now almost 40% larger than Medicaid’s prescription drug purchases.
Hospitals again accounted for 87% of 340B purchases for 2023. Purchases at every 340B covered entity type grew, despite drug prices that grew m ..read more
Drug Channels
3w ago
Informa Connect’s Trade and Channel Strategies
December 10-12, 2024 at the W Hotel in Philadelphia, PA
Drug Channels readers save 10% with code 24DC10*
Pharmacy and distribution models are growing increasingly complex. Stop running in circles—It’s time to unlock proven strategies to propel market access.
What is the secret to success? Trade and Channel Strategies is bringing together industry experts to deliver specific strategies and talk best practices in tackling the latest industry challenges.
As the landscape rapidly evolves, there are only two choices—Adapt or risk falling behind. W ..read more
Drug Channels
3w ago
Today’s guest post comes from Greg Skalicky, President, EVERSANA and Faruk Abdullah, President, Professional Services & Chief Business Officer, EVERSANA
Greg and Faruk walk through the marketplace pressures driving Direct-to-Patient commercialization models. They argue that a technology-enabled infrastructure, combined with clinical and reimbursement support specialists, can improve patients' access to new therapies, shorten the time to therapy, and enable better overall clinical outcomes.
Click here to learn more about EVERSANA’s Direct-to-Patient care model.
Read on for ..read more
Drug Channels
1M ago
A new survey of plan sponsors sheds light on their satisfaction with transparency at large and small pharmacy benefit managers (PBMs).
As you will see, clients remain slightly more satisfied with the perceived transparency of smaller PBMs compared with the Big Three PBMs—CVS Caremark, Express Scripts, and Optum Rx.
However, plan sponsors are dissatisfied with transparency about how both large and small PBMs make money. Smaller PBMs have an edge, but it’s narrower than you might think.
Perhaps PBMs’ clients are unable or unwilling to negotiate better deals, write more effective contracts ..read more